Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: The effect of first-dose area under the concentration time curve on transplant-related outcomes

Bone Marrow Transplantation

Volumn 46, Issue 11, 2011, Pages 1418-1425

  Perkins, J ^a   Field, T ^a   Kim, J ^a   Kharfan Dabaja, M A ^a   Ayala, E ^a   Perez, L ^a   Fernandez, H ^a   Fancher, K ^a   Tate, C ^a   Shaw, L M ^b   Milone, M C ^b   Gardiner, J A ^b   Miller, S ^b   Anasetti, C ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BU; hematopoietic celltransplant; pharmacokinetics

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; FLUDARABINE PHOSPHATE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DISEASE FREE SURVIVAL; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; LEUKEMIA RELAPSE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AREA UNDER CURVE; BUSULFAN; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; VIDARABINE;

EID: 80855124888     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.315     Document Type: Article

References (31)

1. Russell JA, Tran HT, Quinlan BN, Chaudhry A, Duggan P, Brown C et al. Once daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: Study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476. (Pubitemid 35174820)
2. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820-826. (Pubitemid 36917770)
3. De Lima M, Couriel D, Thall PF, Wang Z, Madden T, Jones R et al. Once daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864. (Pubitemid 38970585)
4. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008; 13: 672-684. (Pubitemid 351664062)
5. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230. (Pubitemid 26057312)
6. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909-913. (Pubitemid 27510952)
7. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31-42.
8. Andersson BS, Couriel D, Madden T, Couriel D, Wang X, Tran HT et al. Busulfan systemic exposure relative to regimenrelated toxicity and acute graft vs host disease; defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8: 477-485. (Pubitemid 35174821)
9. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-3060. (Pubitemid 27172594)
10. Kashyap A, Wingard J, Cagnoni P, Jones R, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493-500. (Pubitemid 35174823)
11. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102: 31-35. (Pubitemid 36759632)
12. Sorror ML, Maris MB, Storb R, Baron F, Sandmeier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
13. Chein JW, Sullivan KM. Carbon monoxide diffusion capacity: How low can you go for hematopoietic cell transplantation eligibility? Biol Blood Marrow Transplant 2009; 15: 447-453.
14. Lai WK, Pang CP, Law LK, Wong R, Li CK, Yuen PM. Routine analysis of plasma busulfan by gas chromatographymass fragmentography. Clin Chem 1998; 44: 2506-2510. (Pubitemid 28565663)
15. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation. Ann Intern Med 1993; 118: 255-267. (Pubitemid 23046384)
16. Lobashevsky AL, Senkbeil RW, Townsend JE, Mink CA, Thomas JM. Quantitative analysis of chimerism using a short tandem repeat method on a fluorescent automated DNA sequencer. Clin Lab Haematol 2006; 28: 40-49.
17. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
18. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005; 11: 945-955.
19. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
20. Choudhury JB. Non-parametric confidence interval estimation for competing risks analysis: Application to contraceptive data. Stat Med 2002; 21: 1129-1144. (Pubitemid 34285495)
21. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. JASA 1999; 94: 496-509.
22. Madden T, de Lima M, Thapar N, Nguyen J, Roberson S, Couriel D et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: A comparison with every 6-h dosing. Biol Blood Marrow Transplant 2007; 13: 56-64. (Pubitemid 46044090)
23. Geddes M, Kangarloo B, Naveed F, Quinlan D, Chaudhry MA, Stewart D et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 2008; 14: 220-228.
24. Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C et al. The effect of busulfan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-924. (Pubitemid 30255722)
25. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043-2048. (Pubitemid 36237612)
26. McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B et al. Cyclophosphamide following targeted oral busulfan and conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853-862. (Pubitemid 46902444)
27. Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100: 1201-1207. (Pubitemid 34864272)
28. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12: 954-964.
29. Guilfoyle R, Demers A, Bredeson C, Richardson E, Rubinger M, Szwajcer D et al. Performance status, but notHematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43: 133-139.
30. Sorror JL, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-4254. (Pubitemid 47554249)
31. Wallen H, Gooley TA, Deeg HJ, Pagel JM, Press OW, Appelbaum FR et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23: 3429-3446.